Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osi-027. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 4/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 3/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 3/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 3/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 3/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 3/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 1/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | BMPR2 | Q13873 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osi-027 SCHEMBL22594988 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL976796 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL25062088 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL29929993 | 1.00 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL11971939 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL977589 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL977583 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL977586 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL978894 | 0.99 | MTOR (0.98) | MTORRICTORRPTORMAPKAP1MLST8 | |
| Osi-027 SCHEMBL2697673 | 0.94 | MTOR (0.88) | MTORRICTORRPTORMAPKAP1MLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2075 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-12576069-B2 | Compositions and methods for treating slow-flow vascular malformations | YALE UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| US-12576088-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | NORTHWESTERN UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| CN-114302746-A | Combination therapy comprising an anti-CD 25 antibody drug conjugate and another agent | ADC治疗有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | claimed |
| EP-3976195-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220031673-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | UNIV DREXEL (US) | 2022-02-03 | — | — | US | claimed |
| US-10463743-B2 | Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof | SHANGHAI JIAO TONG UNIVERSITY (CN) | 2019-11-05 | — | — | US | claimed |
| US-20180282818-A1 | Therapeutic Cancer Treatments Based on TP53 Gene Mutations | WISTAR INST (US) | 2018-10-04 | — | — | US | claimed |
| US-8557814-B2 | mTOR inhibitor salt forms | OSI Pharmaceuticals, LLC (US) | 2013-10-15 | — | — | US | claimed |